BeiGene Ltd
For the period ended Sep 30, 2024. Filed Nov 12, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2024 · Filed Nov 12, 2024
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 5. Other Information
(c)
The following table describes for the quarterly period covered by this report each trading arrangement for the purchase or sale of Company securities adopted, modified orterminated by our directors and officers that is either (1) a contract, instruction or written plan intended to satisfy the affirmative defense conditions of Rule 10b5-1(c), or a “Rule 10b5-1 trading arrangement,” or (2) a “non-Rule 10b5-1 trading arrangement” (as defined in Item 408(c) of Regulation S-K):
| Name (Title) | Action Taken (Date of Action) | Type of Trading Arrangement | Nature of Trading Arrangement | Duration of Trading Arrangement | Aggregate Number of Securities |
|---|---|---|---|---|---|
| Dr. Xiaodong Wang(Co-Founder and Director) | Adoption(August 12, 2024) | Rule 10b5-1 trading arrangement | Sale | November 28, 2025 | Stock options and restricted stock units (“RSUs”) equaling up to 334,795 American Depositary Shares (“ADSs”) plus additional sales of ADSs with an aggregate value of approximately US$3.5 million net of commissions and fees associated with the sales. |
| Julia Wang(Former Chief Financial Officer) | Termination(September 3, 2024) | Rule 10b5-1 trading arrangement | Sale | September 3, 2024 | 78,727 ADSs plus an additional number of ADSs subject to RSUs equal to the net number of shares resulting from applicable RSU vestings after sell-to-cover for withholding tax. |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.